Fedratinib Hydrochloride is Used for treating primary or secondary myelofibrosis in adult patients, monitoring thiamine levels, and administering thiamine or a thiamine equivalent. It was first introduced by Bristol-Myers Squibb Co in its drug Inrebic on Aug 16, 2019.

Fedratinib Hydrochloride Patents

Given below is the list of patents protecting Fedratinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Inrebic	US10391094	Compositions and methods for treating myelofibrosis	Jun 04, 2032	Bristol-myers
Inrebic	US11400092	Methods of treating myeloproliferative disorders	Sep 24, 2039	Bristol-myers
Inrebic	US7528143	Bi-aryl meta-pyrimidine inhibitors of kinases	Nov 16, 2031	Bristol-myers
Inrebic	US7825246	Bi-aryl meta-pyrimidine inhibitors of kinases	Dec 16, 2026	Bristol-myers
Inrebic	US8138199	Use of bi-aryl meta-pyrimidine inhibitors of kinases	Jun 30, 2028	Bristol-myers

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳